Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate?

Lung Cancer

Volumn 84, Issue 2, 2014, Pages 97-100

  Martinez, Pablo ^a   Martinez Marti, Alex ^a   Navarro, Alejandro ^a   Cedrés, Susana ^a   Felip, Enriqueta ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Early stage; Locally advanced stage; Non small cell lung cancer; Targeted therapies

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEFITINIB; MELANOMA ANTIGEN 3; MONOCLONAL ANTIBODY; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; TECEMOTIDE; ANGIOGENESIS INHIBITOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ADJUVANT CHEMORADIOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER STAGING; EARLY CANCER; EDITORIAL; ESOPHAGITIS; FEASIBILITY STUDY; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRACHEOESOPHAGEAL FISTULA; TREATMENT INDICATION; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYMOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS;

ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84899482991     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.01.018     Document Type: Editorial

References (36)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA CancerJ Clin 2011, 61(2):69-90. Epub 2011/02/08.
2. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2(8):706-714. Epub 2007/09/01.
3. PORT Meta-analysis Trialists Group Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998, 352(9124):257-263. Epub 1998/08/05.
4. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350(4):351-360. Epub 2004/01/23.
5. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550. Epub 2006/12/15.
6. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957. Epub 2009/08/21.
7. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368(25):2385-2394. Epub 2013/06/04.
8. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388. Epub 2010/06/25.
9. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8):735-742. Epub 2011/07/26.
10. Sequist L.V., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol 2013, 31(27):3327-3334. Epub 2013/07/03.
11. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246. Epub 2012/01/31.
12. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132. Epub 2005/07/15.
13. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczesna A., Juhasz E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11(6):521-529. Epub 2010/05/25.
14. Ready N., Janne P.A., Bogart J., Dipetrillo T., Garst J., Graziano S., et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol 2010, 5(9):1382-1390.
15. Kelly K., Chansky K., Gaspar L.E., Albain K.S., Jett J., Ung Y.C., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008, 26(15):2450-2456.
16. Rigas J.R., Carey M.A., Rubin M.S., Dragnev K.H., Aitken C.L., Ghazal H., et al. Efficacy of maintenance erlotinib versus placebo in patients with unresectable stage III non-small cell lung cancer (NSCLC) following concurrent chemoradiation. J Thorac Oncol 2009, 4:s371.
17. Janjigian Y.Y., Park B.J., Zakowski M.F., Ladanyi M., Pao W., D'Angelo S.P., et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol 2011, 6(3):569-575. Epub 2010/12/15.
18. Goss G.D., O'Callaghan C., Lorimer I., Tsao M.S., Masters G.A., Jett J., et al. Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study. J Clin Oncol 2013, 31(27):3320-3326. Epub 2013/08/28.
19. Soria J.-C., Barlesi F., Besse B., Mazieres J., Merle P., Cadranel J., et al. Results of the prospective, randomized, and customized NSCLC adjuvant phase II trial (IFCT-0801, TASTE trial) from the French Collaborative Intergroup. J Clin Oncol 2013, 31(Suppl. 15):7505. ASCO Meeting Abstracts.
20. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373(9674):1525-1531. Epub 2009/05/05.
21. Govindan R., Bogart J., Stinchcombe T., Wang X., Hodgson L., Kratzke R., et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: cancer and leukemia group B trial 30407. J Clin Oncol 2011, 29(23):3120-3125. Epub 2011/07/13.
22. Blumenschein G.R., Paulus R., Curran W.J., Robert F., Fossella F., Werner-Wasik M., et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011, 29(17):2312-2318. Epub 2011/05/11.
23. Bradley J.D., Paulus R., Komaki R., Masters G.A., Forster K., Schild S.E., et al. A randomized phase III comparison of standard-dose (60Gy) versus high-dose (74Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617. J Clin Oncol 2013, 31(Suppl 15):7501. ASCO Meeting Abstracts.
24. Jeffrey Bradley, Gregory Masters, Chen Hu, George Blumenschein, Jeff Bogart, Steve Schild, et al. An Intergroup randomized phase III comparison of standard-dose (60Gy) versus high-dose (74Gy) chemorradiotherapy +/- cetuximab for stage III Non-Small Cell Lung Cancer: results from RTOG 0617. Journal of Thoracic Oncology. 2013, S3.
25. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21(9):1804-1809. Epub 2010/02/13.
26. Spigel D.R., Hainsworth J.D., Yardley D.A., Raefsky E., Patton J., Peacock N., et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010, 28(1):43-48. Epub 2009/11/11.
27. Socinski M.A., Stinchcombe T.E., Moore D.T., Gettinger S.N., Decker R.H., Petty W.J., et al. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. J Clin Oncol 2012, 30(32):3953-3959. Epub 2012/10/10.
28. http://clinicaltrials.gov/ct2/show/NCT00334815?term=S0533&rank=1.
29. Van den Eynde B.J., van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997, 9(5):684-693.
30. Marchand M., Punt C.J., Aamdal S., Escudier B., Kruit W.H., Keilholz U., et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003, 39(1):70-77. Epub 2002/12/31.
31. Vansteenkiste J., Zielinski M., Linder A., Dahabreh J., Gonzalez E.E., Malinowski W., et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013, 31(19):2396-2403. Epub 2013/05/30.
32. Ulloa-Montoya F., Louahed J., Dizier B., Gruselle O., Spiessens B., Lehmann F.F., et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013, 31(19):2388-2395.
33. Karsten U., von Mensdorff-Pouilly S., Goletz S. What makes MUC1 a tumor antigen?. Tumour Biol 2005, 26(4):217-220.
34. Vlad A.M., Kettel J.C., Alajez N.M., Carlos C.A., Finn O.J. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004, 82:249-293. Epub 2004/02/21.
35. Butts C., Murray N., Maksymiuk A., Goss G., Marshall E., Soulieres D., et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005, 23(27):6674-6681. Epub 2005/09/20.
36. Butts C., Socinski M.A., Mitchell P.L., Thatcher N., Havel L., Krzakowski M., et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2013, Epub 2013/12/18.